Literature DB >> 11239874

Resolution of microsporidial keratoconjunctivitis in an AIDS patient treated with highly active antiretroviral therapy.

S A Martins1, C Muccioli, R Belfort, A Castelo.   

Abstract

PURPOSE: To report the outcome of microsporidial keratoconjunctivitis in a patient with acquired immunodeficiency syndrome (AIDS) after highly active antiretroviral therapy without any specific treatment for microsporidiosis.
METHODS: Case report. A 42-year-old woman diagnosed with AIDS and severe immunodepression (CD4+ of 9 cells/mm(3) and viral load of 460,000/mm(3)), antiretroviral naive, presented with cerebral toxoplasmosis and microsporidial keratoconjunctivitis in the right eye documented by conjunctival scraping and electron microscopy.
RESULTS: The patient was treated with a combination of indinavir, stavudine, and lamivudine, besides sulfadiazine and pyrimethamine. No specific treatment for the microsporidial keratoconjunctivitis was attempted. One month later, the keratoconjunctivitis had disappeared.
CONCLUSION: This case suggests that microsporidial keratoconjunctivitis in the setting of AIDS and severe immunodepression can be effectively managed with highly active antiretroviral therapy alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239874     DOI: 10.1016/s0002-9394(00)00810-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Microsporidia and Acanthamoeba: the role of emerging corneal pathogens.

Authors:  E Y Tu; C E Joslin
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

2.  Outbreak of microsporidial keratoconjunctivitis with rugby sport due to soil exposure.

Authors:  A K H Kwok; J M K Tong; B S F Tang; R W S Poon; W W T Li; K Y Yuen
Journal:  Eye (Lond)       Date:  2013-04-19       Impact factor: 3.775

Review 3.  Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.

Authors:  Jyotirmay Biswas; S Sudharshan
Journal:  Indian J Ophthalmol       Date:  2008 Sep-Oct       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.